Back to top
more

Montes Archimedes Acquisition (ROIV)

(Delayed Data from NSDQ)

$16.04 USD

16.04
4,849,721

-0.08 (-0.50%)

Updated Oct 10, 2025 04:00 PM ET

After-Market: $16.04 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.81%
2Buy17.98%
3Hold9.90%
4Sell5.43%
5Strong Sell2.74%
S&P50011.32%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (85 out of 243)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Analysts Estimate Roivant Sciences Ltd. (ROIV) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Roivant Sciences Ltd. (ROIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

BioAtla, Inc. (BCAB) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

BioAtla, Inc. (BCAB) delivered earnings and revenue surprises of 10.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Geron (GERN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Geron (GERN) delivered earnings and revenue surprises of -11.11% and 156.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 14.29% and 83.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Roivant Sciences Ltd. (ROIV) Soars 5.8: Is Further Upside Left in the Stock?

by Zacks Equity Research

Roivant Sciences Ltd. (ROIV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Roivant Sciences Ltd. (ROIV) delivered earnings and revenue surprises of -60% and 33.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Venus Concept (VERO) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Venus Concept (VERO) delivered earnings and revenue surprises of -100% and 9.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Synlogic, Inc. (SYBX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 4.35% and 49.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Exelixis (EXEL) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Exelixis (EXEL) delivered earnings and revenue surprises of 10% and 7.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in Global Blood (GBT): Can Its 41.4% Jump Turn into More Strength?

by Zacks Equity Research

Global Blood (GBT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cytokinetics (CYTK) delivered earnings and revenue surprises of 77.88% and 2,483.28%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pfizer (PFE) Discloses Autoimmune Drug Deal With Priovant

by Zacks Equity Research

Pfizer (PFE) announces the name of the new company that it formed with its partner, Roivant Sciences (ROIV), to develop and market its dual TYK2/JAK1 inhibitor.

Zacks Equity Research

Here's What to Expect Ahead of BlackBerry's (BB) Q1 Earnings

by Zacks Equity Research

BlackBerry's (BB) first-quarter fiscal 2023 revenues are likely to have benefited from its billings growth and higher demand for IoT and cyber security solutions.